KIM, Jun Hwan,LIM, Seyoung,SEO, Minji,CHOI, Hyun Ho,KIM, Dohoon,JU, Mi Kyeong,PARK, Ju-Young,CHOI, Byung Hyun,LEE, Jun Kyung,KIM, Jong Gyun,NAM, Su Youn,朱美敬,PARK, Ju-Young,朴珠英,CHOI, Byung Hyun,崔秉賢,LEE
申请号：
HK18116583
公开号：
HK1257375A1
申请日:
2018.12.26
申请国别(地区):
HK
年份:
2019
代理人:
摘要：
The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
